Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2022; 10(22): 7968-7972
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7968
Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report
Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan
Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan, Department of Neurosurgery, Peking University First Hospital, Beijing 100034, China
Author contributions: Xu LQ conceived the article; Xu LQ and Wang YJ collected the data; Wang YJ assembled the data; Xu LQ, Wang YJ, Shen SL, Wu Y and Duan HZ provided the study materials, write the manuscript and approved the manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images in October 20, 2021.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Zhou Duan, Doctor, PhD, Chief Doctor, Department of Neurosurgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. duanhongzhou@126.com
Received: February 11, 2022
Peer-review started: February 11, 2022
First decision: May 30, 2022
Revised: June 2, 2022
Accepted: June 21, 2022
Article in press: June 21, 2022
Published online: August 6, 2022
Processing time: 161 Days and 5.3 Hours
Core Tip

Core Tip: Examination of circulating tumor DNA in cell-free cell-free cerebrospinal fluid (CSF) has been shown to be useful for detecting the genomic mutations of tumors in the central nervous system, and osimertinib is considered to be a recent standardized treatment for epidermal growth factor receptor (EGFR) Thr790Met-mutant non-small-cell lung cancer (NSCLC). Hence, we report a patient with EGFR Thr790Met-mutant NSCLC with meningeal carcinomatosis and resistance to gefitinib and propose that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations that may appear earlier than the imaging and CSF findings and thus be helpful for therapy.